HER2-low-positive breast cancer from four neoadjuvant clinical trials

被引：0
|
作者：
Omar, Abeid [1 ]
Arafat, Waleed [1 ]
机构：
[1] Alexandria Univ, Dept Clin Oncol, Alexandria 21131, Egypt
来源：
LANCET ONCOLOGY | 2021年 / 22卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E426 / E426
页数：1
相关论文
共 50 条
  • [1] Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
    Denkert, Carsten
    Seither, Fenja
    Schneeweiss, Andreas
    Link, Theresa
    Blohmer, Jens-Uwe
    Just, Marianne
    Wimberger, Pauline
    Forberger, Almuth
    Tesch, Hans
    Jackisch, Christian
    Schmatloch, Sabine
    Reinisch, Mattea
    Solomayer, Erich F.
    Schmitt, Wolfgang D.
    Hanusch, Claus
    Fasching, Peter A.
    Luebbe, Kristina
    Solbach, Christine
    Huober, Jens
    Rhiem, Kerstin
    Marme, Frederik
    Reimer, Toralf
    Schmidt, Marcus
    Sinn, Bruno, V
    Janni, Wolfgang
    Stickeler, Elmar
    Michel, Laura
    Stoetzer, Oliver
    Hahnen, Eric
    Furlanetto, Jenny
    Seiler, Sabine
    Nekljudova, Valentina
    Untch, Michael
    Loibl, Sibylle
    LANCET ONCOLOGY, 2021, 22 (08): : 1151 - 1161
  • [2] HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
    Miglietta, Federica
    Griguolo, Gaia
    Bottosso, Michele
    Giarratano, Tommaso
    Lo Mele, Marcello
    Fassan, Matteo
    Cacciatore, Matilde
    Genovesi, Elisa
    De Bartolo, Debora
    Vernaci, Grazia
    Amato, Ottavia
    Porra, Francesca
    Conte, PierFranco
    Guarneri, Valentina
    Dieci, Maria Vittoria
    NPJ BREAST CANCER, 2022, 8 (01)
  • [3] HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
    Federica Miglietta
    Gaia Griguolo
    Michele Bottosso
    Tommaso Giarratano
    Marcello Lo Mele
    Matteo Fassan
    Matilde Cacciatore
    Elisa Genovesi
    Debora De Bartolo
    Grazia Vernaci
    Ottavia Amato
    Francesca Porra
    PierFranco Conte
    Valentina Guarneri
    Maria Vittoria Dieci
    npj Breast Cancer, 8
  • [4] Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer
    Shi, Wenjie
    Wan, Xinyu
    He, Jinzhi
    Wang, Ye
    Zhang, Weiwei
    Xu, Yinggang
    Huang, Xiaofeng
    Chen, Rui
    Xu, Lu
    Zha, Xiaoming
    Wang, Jue
    JOURNAL OF INVESTIGATIVE MEDICINE, 2023, 71 (04) : 384 - 393
  • [5] Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
    Poeschke, Patrik
    Fasching, Peter A.
    Adler, Werner
    Ruebner, Matthias
    Beckmann, Matthias W.
    Hack, Carolin C.
    Heindl, Felix
    Hartmann, Arndt
    Erber, Ramona
    Gass, Paul
    CANCERS, 2023, 15 (19)
  • [6] HER2 POSITIVE BREAST CANCER: LESSONS LEARNT FROM RECENT NEOADJUVANT TRIALS
    Piccart, M.
    Saini, K.
    Loi, S.
    Azim, H. A., Jr.
    Metzger-Filho, O.
    Capelan, M.
    Bozovic, I.
    De Azambuja, E.
    ANNALS OF ONCOLOGY, 2011, 22 : 24 - 25
  • [7] Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer
    Shi, Wenjie
    Wan, Xinyu
    Wang, Ye
    He, Jinzhi
    Huang, Xiaofeng
    Xu, Yinggang
    Zhang, Weiwei
    Chen, Rui
    Wang, Lexin
    Zheng, Ran
    Ma, Lingjun
    Li, Xuan
    Xu, Lu
    Zha, Xiaoming
    Wang, Jue
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2023, 49
  • [8] Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: A 10-year dual-center retrospective study
    Li, Y.
    Zhang, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S289 - S289
  • [9] Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: a 10-year dual-center retrospective study
    Li, Yijun
    Maimaitiaili, Amina
    Qu, Fengjiang
    Li, Gefei
    Shi, Bohui
    Wang, Yidi
    Zhang, Jingyi
    He, Jianjun
    Fan, Zhimin
    Zhang, Huimin
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (08): : 3571 - 3581
  • [10] Neoadjuvant treatment for HER2-positive breast cancer
    Takada, Masahiro
    Toi, Masakazu
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
12345